Corient Private Wealth’s Arcturus Therapeutics ARCT Stock Holding History

Corient Private Wealth’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Buy	+17,354	New	+$137K	﹤0.01%	2915

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Corient Private Wealth's ARCT Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Arcturus Therapeutics (ARCT) in Q2 2026: 17,354 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #2915 among its holdings.

135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Corient Private Wealth held 17,354 shares of Arcturus Therapeutics worth $117K as of Q2 2026.
Arcturus Therapeutics was a new Corient Private Wealth position in Q2 2026.
Arcturus Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2915 holding.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.